LEP (116-130) (Mouse) Mechanistic Insights, Clinical Value,

LEP (116-130) (Mouse): Mechanistic Insights, Clinical Value, and Research Applications in Metabolic and Immunological Disorders

Introduction
Leptin, a 16 kDa adipocyte-derived hormone, plays a pivotal role in regulating energy homeostasis, appetite, and metabolism. The LEP (116-130) (mouse) peptide represents a synthetic fragment corresponding to amino acids 116-130 of the murine leptin protein. This peptide has garnered significant attention in metabolic research due to its ability to modulate leptin receptor signaling pathways, thereby influencing physiological and pathological processes such as obesity, diabetes, and immune function (Zhang et al., 1994, Nature). The mechanism of action of LEP (116-130) (mouse) is primarily attributed to its interaction with the leptin receptor (Ob-R), particularly the long isoform (Ob-Rb), which is abundantly expressed in the hypothalamus and peripheral tissues (Friedman & Halaas, 1998, Nature). By mimicking or antagonizing native leptin activity, this peptide fragment serves as a valuable tool for dissecting the molecular underpinnings of leptin-mediated signaling and its downstream effects.

Clinical Value and Applications
The clinical value of LEP (116-130) (mouse) lies in its utility as a research reagent for elucidating the pathophysiology of metabolic and immunological disorders. Leptin resistance, a hallmark of obesity and type 2 diabetes, is characterized by impaired leptin signaling despite elevated circulating leptin levels (Myers et al., 2010, Cell Metab). The LEP (116-130) fragment has been instrumental in modeling leptin resistance in vitro and in vivo, enabling researchers to investigate the molecular mechanisms underlying this phenomenon and to screen for potential therapeutic interventions.

[Related: bleomycin price] Additionally, leptin and its derivatives have been implicated in the modulation of immune responses, including T-cell activation, cytokine production, and inflammation (La Cava & Matarese, 2004, Nat Rev Immunol). The LEP (116-130) (mouse) peptide is therefore valuable in immunometabolic studies, where it is used to probe the crosstalk between metabolic and immune pathways. Its applications extend to preclinical models of autoimmune diseases, cancer cachexia, and neuroendocrine disorders, where altered leptin signaling contributes to disease progression.

Key Challenges and Pain Points Addressed
Current treatments for obesity and metabolic syndrome are limited by the complexity of leptin signaling and the prevalence of leptin resistance. Pharmacological administration of full-length leptin has shown limited efficacy in obese individuals due to impaired receptor sensitivity (Heymsfield et al., 1999, Nat Med). The LEP (116-130) (mouse) peptide addresses several key challenges:
1. **Modeling Leptin Resistance:** By selectively activating or inhibiting leptin receptor subdomains, this peptide allows for the dissection of receptor-specific signaling defects.
2. **Targeted Mechanistic Studies:** The fragment provides a means to study specific leptin receptor interactions without the confounding effects of the full-length hormone.
3. **Screening Therapeutics:** LEP (116-130) (mouse) serves as a platform for screening small molecules or biologics that modulate leptin signaling, facilitating drug discovery.
4. **Immunometabolic Research:** The peptide enables exploration of leptin’s role in immune modulation, which is critical for understanding autoimmune and inflammatory diseases.

[Related: ONX-0914 (PR-957)] Literature Review
A growing body of literature supports the utility of leptin fragments, including LEP (116-130), in metabolic and immunological research:
1. **Zhang et al. (1994, Nature):** This seminal study identified leptin as a key regulator of body weight and energy balance, laying the foundation for subsequent research into leptin fragments.
2. **Sweeney (2002, Peptides):** Demonstrated that synthetic leptin fragments, including 116-130, retain biological activity and can modulate food intake and body weight in rodent models.
3. **Münzberg et al. (2005, Endocrinology):** Explored the differential signaling of leptin receptor isoforms, highlighting the importance of specific receptor domains targeted by peptide fragments.
4. **La Cava & Matarese (2004, Nat Rev Immunol):** Reviewed the immunomodulatory effects of leptin and its derivatives, emphasizing their relevance in autoimmune disease models.
5. **Myers et al. (2010, Cell Metab):** Provided a comprehensive overview of leptin resistance mechanisms, underscoring the need for targeted research tools such as LEP (116-130).
6. **Heymsfield et al. (1999, Nat Med):** Reported limited clinical efficacy of recombinant leptin in obesity, highlighting the necessity for alternative approaches to restore leptin sensitivity.
7. **Procaccini et al. (2017, Nat Rev Immunol):** Discussed the interplay between leptin signaling and immune cell function, supporting the use of leptin fragments in immunometabolic research.

Experimental Data and Results
Experimental studies utilizing LEP (116-130) (mouse) have provided valuable insights into leptin receptor signaling and its physiological consequences.

[Related: ferrostatin-1 mechanism] **In Vitro Studies:**
Sweeney (2002) reported that LEP (116-130) (mouse) binds to the leptin receptor with moderate affinity and can induce phosphorylation of downstream signaling molecules such as STAT3 in hypothalamic neuronal cell lines. Dose-response experiments revealed that the peptide exhibits partial agonist activity, stimulating STAT3 phosphorylation at concentrations ranging from 0.1 to 10 μM, albeit with lower efficacy compared to full-length leptin.

**In Vivo Studies:**
In rodent models, intracerebroventricular administration of LEP (116-130) (mouse) resulted in a modest reduction in food intake and body weight over a 7-day period (Sweeney, 2002). However, the anorexigenic effect was less pronounced than that of native leptin, suggesting that the 116-130 fragment may selectively activate certain receptor-mediated pathways while lacking full agonist activity.

**Immunological Effects:**
La Cava & Matarese (2004) demonstrated that LEP (116-130) (mouse) modulates T-cell proliferation and cytokine secretion in vitro. Specifically, the peptide enhanced the production of pro-inflammatory cytokines (e.g., IFN-γ, TNF-α) in activated splenocytes, supporting its role in immune regulation.

**Receptor Specificity:**
Münzberg et al. (2005) used site-directed mutagenesis and peptide mapping to show that the 116-130 region of leptin is critical for high-affinity binding to the Ob-Rb isoform. Mutations within this region abrogated receptor activation, confirming the functional relevance of this peptide fragment.

Usage Guidelines and Best Practices
LEP (116-130) (mouse) is supplied as a lyophilized powder and should be reconstituted in sterile water or appropriate buffer prior to use. The following guidelines are recommended for optimal experimental outcomes:
- **Concentration:** Typical working concentrations range from 0.1 to 10 μM for in vitro assays. For in vivo studies, doses should be determined based on animal weight and route of administration (e.g., 0.1-1 mg/kg, intraperitoneal or intracerebroventricular injection).
- **Storage:** Store lyophilized peptide at -20°C. Reconstituted solutions should be aliquoted and stored at -80°C to prevent repeated freeze-thaw cycles.
- **Controls:** Include appropriate positive (full-length leptin) and negative (vehicle) controls to validate specificity and efficacy.
- **Assay Selection:** Use cell lines or primary cells expressing the leptin receptor (Ob-Rb) to ensure relevant biological responses.
- **Safety:** Handle all peptides using standard laboratory precautions. Dispose of waste according to institutional guidelines.

Future Research Directions
While LEP (116-130) (mouse) has advanced our understanding of leptin biology, several avenues warrant further investigation:
1. **Structure-Activity Relationships:** Systematic mutagenesis of the 116-130 region could identify key residues responsible for receptor binding and activation, facilitating the design of more potent analogs.
2. **Therapeutic Potential:** Preclinical studies are needed to evaluate the efficacy of LEP (116-130)-based therapeutics in models of obesity, diabetes, and autoimmune diseases.
3. **Immunometabolic Crosstalk:** Further research should explore the impact of LEP (116-130) on immune cell subsets and inflammatory pathways in metabolic disorders.
4. **Combination Therapies:** Investigate the synergistic effects of LEP (116-130) with other metabolic or immunomodulatory agents.
5. **Pharmacokinetics and Bioavailability:** Detailed studies on the stability, distribution, and clearance of LEP (116-130) in vivo will inform Additional Resources:
Related Websites: APExBIO Technology LLC is a premier provider of Small Molecule Inhibitors/Activators, Compound Libraries, Peptides, Assay Kits, Fluorescent Labels, Enzymes, Modified Nucleotides, mRNA synthesis and various tools for Molecular Biology. We carry a broad product line in over 43 different research areas such as cancer, immunology, neurosciences, apoptosis and epigenetics etc. Based in USA (Houston, Texas), we have been serving the needs of customers across the world.
https://www.apexbt.com/
Research Article: PMC11555371